Cantabio Pharmaceuticals Stock Net Income
| CTBO Stock | USD 1.01 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Cantabio Pharmaceuticals' long-term financial health and intrinsic value.
Cantabio |
Cantabio Pharmaceuticals Company Net Income Analysis
Cantabio Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cantabio Pharmaceuticals Net Income | (2.01 M) |
Most of Cantabio Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cantabio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cantabio Pharmaceuticals reported net income of (2.01 Million). This is 100.59% lower than that of the Healthcare sector and 102.87% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.35% higher than that of the company.
Cantabio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cantabio Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cantabio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cantabio Pharmaceuticals by comparing valuation metrics of similar companies.Cantabio Pharmaceuticals is currently under evaluation in net income category among its peers.
Cantabio Fundamentals
| Return On Asset | -4.71 | |||
| Current Valuation | 1.69 M | |||
| Shares Outstanding | 22.54 K | |||
| Shares Owned By Insiders | 70.01 % | |||
| Price To Earning | (1.00) X | |||
| EBITDA | (1.39 M) | |||
| Net Income | (2.01 M) | |||
| Cash And Equivalents | 283.37 K | |||
| Cash Per Share | 12.57 X | |||
| Current Ratio | 0.15 X | |||
| Book Value Per Share | (97.77) X | |||
| Cash Flow From Operations | (623.35 K) | |||
| Earnings Per Share | (130.83) X | |||
| Beta | 1.31 | |||
| Market Capitalization | 563.6 K | |||
| Total Asset | 109.43 K | |||
| Retained Earnings | (996 K) | |||
| Working Capital | (370 K) | |||
| Current Asset | 52 K | |||
| Current Liabilities | 422 K | |||
| Z Score | -55.8 | |||
| Net Asset | 109.43 K |
About Cantabio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cantabio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cantabio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cantabio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Cantabio Pink Sheet
Cantabio Pharmaceuticals financial ratios help investors to determine whether Cantabio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cantabio with respect to the benefits of owning Cantabio Pharmaceuticals security.